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Abstract
Myelin oligodendrocyte glycoprotein (MOG) antibody disease (MOG-AD) is now recognised as a nosological entity with 
specific clinical and paraclinical features to aid early diagnosis. Although no age group is exempt, median age of onset is 
within the fourth decade of life, with optic neuritis being the most frequent presenting phenotype. Disease course can be 
either monophasic or relapsing, with subsequent relapses most commonly involving the optic nerve. Residual disability 
develops in 50–80% of patients, with transverse myelitis at onset being the most significant predictor of long-term outcome. 
Recent advances in MOG antibody testing offer improved sensitivity and specificity. To avoid misdiagnosis, MOG antibody 
testing should be undertaken in selected cases presenting clinical and paraclinical features that are felt to be in keeping with 
MOG-AD, using a validated cell-based assay. MRI characteristics can help in differentiating MOG-AD from other neuro-
inflammatory disorders, including multiple sclerosis and neuromyelitis optica. Cerebrospinal fluid oligoclonal bands are 
uncommon. Randomised control trials are limited, but observational open-label experience suggests a role for high-dose 
steroids and plasma exchange in the treatment of acute attacks, and for immunosuppressive therapies, such as steroids, oral 
immunosuppressants and rituximab as maintenance treatment.
Keywords Myelin oligodendrocyte glycoprotein (MOG) antibodies · Multiple sclerosis (MS) · Neuromyelitis optica 
(NMO) · Optic neuritis (ON) · Cerebrospinal fluid (CSF) · MRI
Introduction
Myelin oligodendrocyte glycoprotein (MOG) is a glycopro-
tein located on the myelin surface and found exclusively 
in the central nervous system (CNS) [1, 2]. Although its 
exact role remains unclear, it is thought to act as a cellular 
adhesive molecule, to be involved as a regulator of oligoden-
drocyte microtubule stability and to mediate complement 
cascade [3].
MOG antibodies have been extensively studied over the 
last 30 years, with some early experimental studies hypoth-
esising a pathogenic role in CNS inflammatory diseases [4, 
5]. This hypothesis was later supported by their discovery in 
the sera and cerebrospinal fluid (CSF) of patients with multi-
ple sclerosis (MS), using techniques such as enzyme-linked 
immunosorbent assay and Western blot [6–11]. However, 
the more recent development of highly sensitive and spe-
cific methods for MOG antibody detection using cell-based 
assays, along with new diagnostic classification of similar 
neuroinflammatory conditions, has made it possible to iden-
tify a subset of patients with antibodies to MOG who express 
a clinical phenotype distinct from MS or from neuromyelitis 
optica (NMO) [12–15]. Therefore, MOG antibody disease 
(MOG-AD) is now recognised as a distinct nosological 
entity with specific management and therapeutic require-
ments. In this article, we review the clinical features, investi-
gations and challenges of managing patients with MOG-AD.
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Clinical features of MOG antibody disease
MOG-AD is an inflammatory demyelinating condition 
of the CNS characterised by a monophasic or relapsing 
course of neurological dysfunction, which does not meet 
the typical criteria for MS or other known neuroinflamma-
tory conditions and occurs in the presence of serum MOG 
antibodies detected using specific cell-based assays [16].
Although in most cases demyelination associated with 
MOG antibodies occurs without any apparent inciting or 
predisposing event/illness, it has been associated with 
demyelinating N-methyl-d-aspartate receptor encephali-
tis, post-infectious demyelination following herpes sim-
plex virus, Borrelia and Epstein–Barr virus infections and, 
more rarely, with typical relapsing MS [17–27]. Whether 
MOG antibodies play a pathogenic role in all these condi-
tions, or if they represent a bystander effect or epiphenom-
enon, remains unclear [28].
MOG-AD can occur in all decades of life, with a slight 
predominance in women and with median age of onset in 
the early to mid-thirties [17, 18, 29–33]. The most com-
mon presenting feature is optic neuritis (ON), occurring 
in 54–61% of patients, followed by myelitis, acute dis-
seminated encephalomyelitis (ADEM) or an ADEM-like 
presentation (e.g., brainstem attack) [18, 29, 31, 32].
A relapsing course has been reported in 44–83% of 
patients [18, 29, 32] and more commonly involves the 
optic nerve [30–32]. MOG-positive ON is frequently 
bilateral and associated with optic nerve head swelling 
[34, 35]. The impact of relapses on disability is variable: 
some studies report no difference between monophasic and 
relapsing disease courses, [29] whilst others report wors-
ening disability associated with higher relapse frequency 
[32]. In case-based series, residual disability develops in 
50–80% of patients, [18, 31, 32] with transverse myelitis 
at onset being the most significant predictor of long-term 
disability [32]. Several case-based series of seizures asso-
ciated with MOG-AD have also been reported [36–38].
At presentation, MOG-positive patients are thought to be 
at lower risk of further relapses than aquaporin 4 (AQP4)-
positive patients [29] and have better visual and motor 
outcomes [29, 32]. In comparison to children with AQP4-
positive neuromyelitis optica spectrum disorder (NMOSD), 
those with MOG-AD tend to be younger, less likely to pre-
sent with area postrema syndrome, but more likely to present 
with ADEM. In addition, they tend to have a longer time 
to relapse and lower disability at follow-up (2 years) [17]. 
Compared to AQP4-positive ON, MOG-positive patients 
have better visual field outcomes, [39] although recurrence 
of ON is significantly more frequent [40].
Table 1 summarises the clinical and paraclinical fea-
tures of MOG-AD, as well as the characteristics that help 
in distinguishing MOG-AD from more common forms of 
neuroinflammation, i.e., MS and NMO.
Paraclinical investigations for MOG 
antibody disease
Magnetic resonance imaging (MRI)
Brain MRI scans are abnormal in approximately 45% of 
patients at onset [29, 31], with percentages increasing later 
in the course of the disease (i.e., up to 77% of patients) [18]. 
The majority have bilateral lesions at onset [29, 30] and 
around one-third have sub-tentorial lesions [18], predomi-
nantly in the brainstem [29]. Typically, lesions are few (three 
or less) and appear as “fluffy”, i.e., poorly demarcated hyper-
intensities on T2-weighted images. Dawson’s fingers, U- or 
S-shaped lesions and ovoid lesions adjacent to the body of 
lateral ventricles are found less commonly [29, 46]. When 
compared to MS-associated ON or AQP4-positive NMOSD-
associated ON, the MRI appearance of the optic nerve in 
MOG-associated ON is more oedematous and shows exten-
sive inflammatory lesions, usually sparing chiasm and optic 
tracts [35]. Thalamic and pontine lesions are more common 
in MOG-AD compared to AQP4-positive disease [29]. In 
children, bilateral thalamic lesions at onset are frequent and 
can be found in about 60% of patients [30]. Compared to 
AQP4-positive patients, cerebellar peduncle lesions are only 
found in MOG-positive children [17].
Just over half of MOG-AD patients have T2 hyperintense 
lesions in the spinal cord, with most lesions being short and 
predominantly occurring in the cervical or thoracic region 
[18]. In a study that explored MRI appearances in children, 
around 27% had abnormal initial spinal cord MRI scans, 
two-third of which showed a longitudinally extensive trans-
verse myelitis (LETM) [30].
Cerebrospinal fluid
CSF pleocytosis occurs in 44–85% of patients [18, 29, 31, 
32] and is more common in children [30, 31]. Positive oligo-
clonal bands (OCBs) are unusual, occurring in only 6–17%, 
[18, 29–32] and CSF protein is raised in around a third of 
cases [31].
Serum
It is currently recommended that MOG antibody immuno-
globulin G (IgG) is detected in serum, using a cell-based 
assay (indirect fluorescence test or fluorescence-activated 
cell sorting) and employing full length human MOG as the 
target antigen [12, 13, 47]. As false positive MOG anti-
body results can occur, testing for MOG antibodies should 
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be restricted to selected cases only, whereby the clinical and 
paraclinical features are felt to be in keeping with MOG-AD 
[16].
MOG antibody titres have been found to be higher in 
relapse than in remission [29]. A decreasing titre is usu-
ally found in a monophasic disease course and conversion to 
antibody negativity, which has been shown to occur within 
around 8–36 months from an acute event, has been associ-
ated with no further relapses [18, 32]. However, following a 
negative result, antibodies can become positive again, even 
after a few years [32, 47]. In children, persisting high-titre 
MOG antibodies (e.g., over 24 months) are associated with 
a risk of relapse [20].
There is no definite consensus regarding regular antibody 
monitoring. However, as antibodies can increase in relapse 
and can subsequently become negative, it could be argued 
that there is a role for regular monitoring at diagnosis, as 
well as throughout the course of MOG-AD, when reduced 
antibody levels may indicate disease remission. Some have 
suggested that a re-test interval of 6–12 months may be help-
ful [16]. Table 2 summarises when MOG antibody testing 
is indicated.
Biopsy
In brain lesions of patients with positive MOG antibod-
ies and the suspicion of MOG-AD, neuropathology seems 
compatible with pattern II histopathology of MS, i.e., with 
lesions presenting complement and IgG deposits at the sites 
of ongoing demyelination [22, 48].
MOG antibody positivity and the diagnosis 
of MOG‑AD: “red flags”
The 2018 International Recommendations have highlighted 
“red flags” that should prompt a physician to doubt the rel-
evance of a positive result [16]. In these cases, re-testing is 
advised, preferably using a different cell-based assay, and 
expert-opinion should be sought. “Red flags” include pro-
gressive disease; sudden onset of symptoms or continuous 
worsening of symptoms over weeks; combined central and 
peripheral demyelination, as MOG is not expressed in the 
peripheral nervous system; a MRI lesion adjacent to the lat-
eral ventricle that is ovoid/round or associated with an infe-
rior temporal lobe lesion, or Dawson’s finger-type lesions; 
an active brain MRI over time with silent increase in lesion 
burden between relapses; bi- or tri-specific measles, rubella 
and zoster virus reaction in the CSF; serum MOG-IgG levels 
at or just barely above the assay-specific cut-off, especially 
if the clinical picture is atypical; positive MOG-IgM and/or 
MOG-IgA result with negative MOG-IgG; MOG-IgG posi-
tivity in the CSF, but not in the serum, given that MOG-IgG 
is typically produced extra-thecally; AQP4-IgG/MOG-IgG 
“double-positive” test results, which are very rare and should 
prompt re-testing for both antibodies [16]. In all these cases, 
caution should be exerted in diagnosing MOG-AD and clini-
cal and paraclinical follow-up is advised.
Pharmacological management 
of MOG antibody disease
Thus far, there are no controlled treatment trials in MOG-AD 
and observational, open-label experience is limited. There-
fore, care must be taken when interpreting or extrapolating 
results from studies or reports. Due to these limitations, cur-
rent treatment protocols for MOG-AD tend to follow those 
of AQP4− NMO.
Acute treatment
Intravenous methylprednisolone (IVMP) for the treatment 
of MOG antibody positive ON and/or myelitis (dose rang-
ing from 1 to 2 g once a day for 3–5 days) has been reported 
to be effective in some cases, with partial or no recovery 
in 50%. Even if treatment with IVMP is effective initially, 
further courses may not be [33].
Plasma exchange (regime varying from three to five 
cycles) is more commonly used as a second-line treatment 
following steroid resistance and can result in around 40% of 
cases of MOG antibody ON and/or myelitis having a com-
plete or almost complete recovery [33].
Table 2  When to test for MOG antibody
MOG myelin oligodendrocyte glycoprotein, MOG-AD myelin oligodendrocyte glycoprotein antibody disease
Test if Clinical/paraclinical features are suggestive of MOG-AD (2018 International Recommendations) [16]
Diagnosis of MS is made, interferon beta or natalizumab has been started, but efficacy is unexpect-
edly poor and clinical/paraclinical features are compatible with MOG-AD
Re-test if MOG antibody positive, but clinical/paraclinical features not suggestive of MOG-AD (see “MOG 
antibody positivity and the diagnosis of MOG-AD: “red flags””)
Clinical/paraclinical features continue to be suggestive of MOG-AD, but MOG antibody is negative
Likelihood of further events is sought, following MOG-AD diagnosis
Journal of Neurology 
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Disease‑modifying treatment
Long-term treatments with prednisolone (dose > 10 mg/
day for patients > 40  kg in weight and > 5  mg for 
patients ≤ 40 kg in weight [31]), intravenous immuno-
globulins (induction course dose of 2 g/kg with subse-
quent monthly doses of 1 g/kg/infusion [31]), rituximab, 
mycophenolate mofetil, methotrexate or azathioprine 
have all been reported to reduce annualised relapse rate in 
MOG-AD [31, 33, 37]. However, treatment with rituximab 
can be associated with new attacks within the few weeks 
following the first infusion, possibly due to a temporary 
increase in B-cell activating factor and autoantibody 
levels, as also observed in some AQP4-positive NMO 
patients [33]. Although numbers are small, treatment with 
natalizumab has been shown to be ineffective in preventing 
relapses, whereas treatment with ofatumumab was able to 
reduce annualised relapse rate from 2.1 to 0.66 [33]. One 
study found that the rate of treatment failure was lower in 
patients on maintenance steroids (5%; median treatment 
duration of 10 months) compared to non-steroidal main-
tenance therapies (38%) [31].
The role of oral steroids as adjunctive treatment with 
immunosuppressants remains unclear. A study found that 
patients with MOG antibody ON and/or myelitis treated with 
azathioprine, but not adjunctively with oral steroids, expe-
rienced relapses more commonly than patients who under-
went combination therapy [33]. Furthermore, relapses seem 
to occur more frequently when oral prednisolone doses are 
Fig. 1  Management of MOG-AD. This proposed therapeutic manage-
ment of MOG-AD is based on current evidence. Acute treatment with 
steroids and, if needed, subsequent plasma exchange are advised as 
soon as possible after an acute event. After diagnosis and, usually, 
acute treatment, initiation of disease-modifying therapy is advised. 
The choice of the disease-modifying agent should be guided by the 
presence or absence of poor prognostic factors for recurrence and/
or disability. On this basis, treatment may require a prolonged taper 
with oral steroids (advised in the absence of poor prognostic factors) 
or the use of oral immunosuppressants or intravenous immunoglobu-
lins along with oral steroids (advised as first choice in the presence 
of poor prognostic factors). If a lack of response to immunosuppres-
sants is demonstrated or a disabling recurrence of the disease occurs 
after cessation of oral steroids, it is appropriate to consider monoclo-
nal antibodies. While it is reasonable and common practice to treat 
relapsing patients with long-term immunosuppression, the duration of 
disease-modifying treatment remains uncertain. CNS central nervous 
system, MOG-AD myelin oligodendrocyte glycoprotein antibody dis-
ease, MOG myelin oligodendrocyte glycoprotein, IV intravenous
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dropped below 10 mg/day or early after steroid cessation 
[31, 32].
Treatment with interferon beta has been shown to be inef-
fective and can increase disease activity [33, 37]. Similarly, 
glatiramer acetate has been shown to be ineffective when 
administered in children [37].
Figure 1 summarises the proposed management of MOG-
AD, based on current evidence.
Conclusions
The diagnosis of MOG-AD is crucial to plan appropriate 
management. Suggestive clinical and paraclinical features, 
in association with MOG antibody positivity, aid the identifi-
cation of MOG-AD from other inflammatory demyelinating 
diseases, but, in many cases, a definitive diagnosis remains 
difficult. Therefore, the definition of MOG-AD-specific 
diagnostic criteria, as well as the identification of markers of 
disease status, remains a goal of research. Once the disease 
has been diagnosed, uncertainty remains over the best treat-
ment approach and clinical trials for the pharmacological 
management of MOG-AD are still needed.
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